Aggregation of α-synuclein contributes to the formation of Lewy bodies and neurites, the pathologic hallmarks of Parkinson disease (PD) and α-synucleinopathies. Although a number of human mutations have been identified in familial PD, the mechanisms that promote α-synuclein accumulation and toxicity are poorly understood. Here, we report that hyperactivity of the nonreceptor tyrosine kinase c-Abl critically regulates α-synuclein–induced neuropathology. In mice expressing a human α-synucleinopathy–associated mutation (hA53Tα-syn mice), deletion of the gene encoding c-Abl reduced α-synuclein aggregation, neuropathology, and neurobehavioral deficits. Conversely, overexpression of constitutively active c-Abl in hA53Tα-syn mice accelerated α-synuclein aggregation, neuropathology, and neurobehavioral deficits. Moreover, c-Abl activation led to an age-dependent increase in phosphotyrosine 39 α-synuclein. In human postmortem samples, there was an accumulation of phosphotyrosine 39 α-synuclein in brain tissues and Lewy bodies of PD patients compared with age-matched controls. Furthermore, in vitro studies show that c-Abl phosphorylation of α-synuclein at tyrosine 39 enhances α-synuclein aggregation. Taken together, this work establishes a critical role for c-Abl in α-synuclein–induced neurodegeneration and demonstrates that selective inhibition of c-Abl may be neuroprotective. This study further indicates that phosphotyrosine 39 α-synuclein is a potential disease indicator for PD and related α-synucleinopathies.
Saurav Brahmachari, Preston Ge, Su Hyun Lee, Donghoon Kim, Senthilkumar S. Karuppagounder, Manoj Kumar, Xiaobo Mao, Joo Ho Shin, Yunjong Lee, Olga Pletnikova, Juan C. Troncoso, Valina L. Dawson, Ted M. Dawson, Han Seok Ko
Title and authors | Publication | Year |
---|---|---|
Preclinical studies and transcriptome analysis in a model of Parkinson’s disease with dopaminergic ZNF746 expression
Kim JH, Yang S, Kim H, Vo DK, Maeng HJ, Jo A, Shin JH, Shin JH, Baek HM, Lee GH, Kim SH, Lim KH, Dawson VL, Dawson TM, Joo JY, Lee Y |
Molecular Neurodegeneration | 2025 |
Alpha-Synuclein Phosphomimetic Y39E and S129D Knock-In Mice Show Cytosolic Alpha-Synuclein Localization without Developing Neurodegeneration or Motor Deficits
Kim Y, Vaidya B, McInnes J, Zoghbi HY |
eNeuro | 2025 |
Advancements in Genetic and Biochemical Insights: Unraveling the Etiopathogenesis of Neurodegeneration in Parkinson’s Disease
Ratan Y, Rajput A, Pareek A, Pareek A, Jain V, Sonia S, Farooqui Z, Kaur R, Singh G |
Biomolecules | 2024 |
The identification of c-Abl inhibitors as potential agents for Parkinson's disease: a preliminary in silico approach.
Rymbai E, Roy D, Jupudi S, Srinivasadesikan V |
Molecular Diversity | 2024 |
A Phase I, Randomized, SAD, MAD, and PK Study of Risvodetinib in Older Adults and Parkinson's Disease.
Werner MH, Olanow CW, McGarry A, Meyer C, Kruger S, Klint C, Pellecchia J, Walaker S, Ereshefsky L, Blob L, Hassman H, Rodriguez C, Samara E, Safirstein B, Ellenbogen A |
Journal of Parkinson's disease | 2024 |
Phosphorylation and O-GlcNAcylation at the same α-synuclein site generate distinct fibril structures.
Hu J, Xia W, Zeng S, Lim YJ, Tao Y, Sun Y, Zhao L, Wang H, Le W, Li D, Zhang S, Liu C, Li YM |
Nature Communications | 2024 |
Glutamate Receptors and C-ABL Inhibitors: A New Therapeutic Approach for Parkinson's Disease.
Shejul PP, Doshi GM |
Central nervous system agents in medicinal chemistry | 2024 |
AN UPDATE ON MULTIPLE SYSTEM ATROPHY
Stankovic I, Kuijpers M, Kaufmann H |
Current Opinion in Neurology | 2024 |
Protein modification in neurodegenerative diseases
Ramazi S, Dadzadi M, Darvazi M, Seddigh N, Allahverdi A |
MedComm | 2024 |
Posttranslational Modifications of α-Synuclein, Their Therapeutic Potential, and Crosstalk in Health and Neurodegenerative Diseases
Hassanzadeh K, Liu J, Maddila S, Mouradian MM |
Pharmacological Reviews | 2024 |
Dual inhibition of aminoacyl-tRNA synthetase interacting multifunctional protein-2 and α-synuclein by steroid derivative is neuroprotective in Parkinson's model.
Shin JY, Ha MW, Kim JH, Cheon J, Lee GH, Paek SM, Lee Y |
iScience | 2024 |
Post-translational modifications of soluble α-synuclein regulate the amplification of pathological α-synuclein
Zhang S, Zhu R, Pan B, Xu H, Olufemi MF, Gathagan RJ, Li Y, Zhang L, Zhang J, Xiang W, Kagan EM, Cao X, Yuan C, Kim SJ, Williams CK, Magaki S, Vinters HV, Lashuel HA, Garcia BA, Petersson EJ, Trojanowski JQ, Lee VM, Peng C |
Nature Neuroscience | 2023 |
The Management of Parkinson’s Disease: An Overview of the Current Advancements in Drug Delivery Systems
Nakmode DD, Day CM, Song Y, Garg S |
Pharmaceutics | 2023 |
Alpha synuclein post translational modifications: potential targets for Parkinson’s disease therapy?
Brembati V, Faustini G, Longhena F, Bellucci A |
Frontiers in molecular neuroscience | 2023 |
α-Synuclein oligomers and fibrils: partners in crime in synucleinopathies
Bigi A, Cascella R, Cecchi C |
Neural Regeneration Research | 2023 |
The Role of c-Abl Tyrosine Kinase in Brain and Its Pathologies
Motaln H, Rogelj B |
Cells | 2023 |
The Bidirectional Interplay of α-Synuclein with Lipids in the Central Nervous System and Its Implications for the Pathogenesis of Parkinson’s Disease
Battis K, Xiang W, Winkler J |
International journal of molecular sciences | 2023 |
Non-invasive systemic viral delivery of human alpha-synuclein mimics selective and progressive neuropathology of Parkinson’s disease in rodent brains
Bérard M, Martínez-Drudis L, Sheta R, El-Agnaf OM, Oueslati A |
Molecular Neurodegeneration | 2023 |
c-Abl Phosphorylates MFN2 to Regulate Mitochondrial Morphology in Cells under Endoplasmic Reticulum and Oxidative Stress, Impacting Cell Survival and Neurodegeneration
Martinez A, Lamaizon CM, Valls C, Llambi F, Leal N, Fitzgerald P, Guy C, Kamiński MM, Inestrosa NC, van Zundert B, Cancino GI, Dulcey AE, Zanlungo S, Marugan JJ, Hetz C, Green DR, Alvarez AR |
Antioxidants | 2023 |
Development and validation of an expanded antibody toolset that captures alpha-synuclein pathological diversity in Lewy body diseases
Altay MF, Kumar ST, Burtscher J, Jagannath S, Strand C, Miki Y, Parkkinen L, Holton JL, Lashuel HA |
npj Parkinson's Disease | 2023 |
Soluble alpha-synuclein post-translational modifications: unexpected regulators of pathological alpha-synuclein amplification
Kapila S, Sun Y, Peng C, Zhang S |
Neural Regeneration Research | 2023 |
Genetic modifiers of synucleinopathies—lessons from experimental models
Lee RM, Koh TW |
2023 | |
Emerging Therapeutic Strategies for Parkinson’s Disease and Future Prospects: A 2021 Update
N Gouda, A Elkamhawy, J Cho |
Biomedicines | 2022 |
Consequences of variability in α-synuclein fibril structure on strain biology
S Holec, S Liu, A Woerman |
Acta Neuropathologica | 2022 |
Emerging targets signaling for inflammation in Parkinson’s disease drug discovery
R Khairnar, N Parihar, K Prabhavalkar, L Bhatt |
Metabolic Brain Disease | 2022 |
Association of p53 with Neurodegeneration in Parkinson’s Disease
Q Luo, W Sun, Y Wang, J Li, D Li, E Tan |
Parkinson's Disease | 2022 |
Conformational strains of pathogenic amyloid proteins in neurodegenerative diseases
D Li, C Liu |
Nature Reviews Neuroscience | 2022 |
Phase-Separated Subcellular Compartmentation and Related Human Diseases
Zhang L, Wang S, Wang W, Shi J, Stovall DB, Li D, Sui G |
International journal of molecular sciences | 2022 |
Protein interaction networks in neurodegenerative diseases: From physiological function to aggregation
Calabrese G, Molzahn C, Mayor T |
The Journal of biological chemistry | 2022 |
Role of post-translational modifications on the alpha-synuclein aggregation-related pathogenesis of Parkinson’s disease
Yoo H, Lee J, Kim B, Moon H, Jeong H, Lee K, Song WJ, Hur JK, Oh Y |
BMB Reports | 2022 |
α-Synuclein fibril-specific nanobody reduces prion-like α-synuclein spreading in mice
Butler YR, Liu Y, Kumbhar R, Zhao P, Gadhave K, Wang N, Li Y, Mao X, Wang W |
Nature Communications | 2022 |
c-Abl kinase at the crossroads of healthy synaptic remodeling and synaptic dysfunction in neurodegenerative diseases
Gutiérrez DA, Chandía-Cristi A, Yáñez MJ, Zanlungo S, Álvarez AR |
Neural Regeneration Research | 2022 |
Single residue modulators of amyloid formation in the N-terminal P1-region of α-synuclein
Ulamec SM, Maya-Martinez R, Byrd EJ, Dewison KM, Xu Y, Willis LF, Sobott F, Heath GR, van Oosten Hawle P, Buchman VL, Radford SE, Brockwell DJ |
Nature Communications | 2022 |
Rosmarinic Acid Attenuates Rotenone-Induced Neurotoxicity in SH-SY5Y Parkinson’s Disease Cell Model through Abl Inhibition
Han X, Han B, Zhao Y, Li G, Wang T, He J, Du W, Cao X, Gan J, Wang Z, Zheng W |
Nutrients | 2022 |
Nilotinib in Parkinson's disease: A systematic review and meta-analysis
Xie X, Yuan P, Kou L, Chen X, Li J, Li Y |
Frontiers in aging neuroscience | 2022 |
Roles for c-Abl in postoperative neurodegeneration.
Feng L, Fu S, Yao Y, Li Y, Xu L, Zhao Y, Luo L |
International journal of medical sciences | 2022 |
Cell Biology of Parkin: Clues to the Development of New Therapeutics for Parkinson's Disease.
Patel J, Panicker N, Dawson VL, Dawson TM |
CNS Drugs | 2022 |
c-Abl Regulates the Pathological Deposition of TDP-43 via Tyrosine 43 Phosphorylation
Lee S, Ryu HG, Kweon SH, Kim H, Park H, Lee KH, Jang SM, Na CH, Kim S, Ko HS |
Cells | 2022 |
The c-Abl/p73 pathway induces neurodegeneration in a Parkinson's disease model
Marín T, Valls C, Jerez C, Huerta T, Elgueta D, Vidal RL, Alvarez AR, Cancino GI |
2022 | |
Lymphocyte Activation Gene 3 (Lag3) Contributes to α-Synucleinopathy in α-Synuclein Transgenic Mice
H Gu, X Yang, X Mao, E Xu, C Qi, H Wang, S Brahmachari, B York, M Sriparna, A Li, M Chang, P Patel, VL Dawson, TM Dawson |
Frontiers in cellular neuroscience | 2021 |
α-synuclein aggregates induce c-Abl activation and dopaminergic neuronal loss by a feed-forward redox stress mechanism
S Ghosh, SJ Won, J Wang, R Fong, NJ Butler, A Moss, C Wong, J Pan, J Sanchez, A Huynh, L Wu, FP Manfredsson, RA Swanson |
Progress in Neurobiology | 2021 |
The cell biology of Parkinson’s disease
N Panicker, P Ge, VL Dawson, TM Dawson |
The Journal of Cell Biology | 2021 |
Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease
LM Oliveira, T Gasser, R Edwards, M Zweckstetter, R Melki, L Stefanis, HA Lashuel, D Sulzer, K Vekrellis, GM Halliday, JJ Tomlinson, M Schlossmacher, PH Jensen, J Schulze-Hentrich, O Riess, WD Hirst, O El-Agnaf, B Mollenhauer, P Lansbury, TF Outeiro |
npj Parkinson's Disease | 2021 |
Parkinson’s Disease Dementia: Synergistic Effects of Alpha-Synuclein, Tau, Beta-Amyloid, and Iron
J Han, Y Fan, P Wu, Z Huang, X Li, L Zhao, Y Ji, M Zhu |
Frontiers in aging neuroscience | 2021 |
Expanding the role of proteasome homeostasis in Parkinson’s disease: beyond protein breakdown
M Bi, X Du, Q Jiao, , H Jiang |
Cell Death and Disease | 2021 |
Preclinical Detection of Alpha-Synuclein Seeding Activity in the Colon of a Transgenic Mouse Model of Synucleinopathy by RT-QuIC
JY Han, C Shin, YP Choi |
Viruses | 2021 |
Hierarchical chemical determination of amyloid polymorphs in neurodegenerative disease
D Li, C Liu |
Nature Chemical Biology | 2021 |
c-Abl Tyrosine Kinase-Mediated Neuronal Apoptosis in Subarachnoid Hemorrhage by Modulating the LRP-1-Dependent Akt/GSK3β Survival Pathway
C Yan, H Yu, Y Liu, P Wu, C Wang, H Zhao, K Yang, Q Shao, Y Zhong, W Zhao, J Li, N Liu, J Di, C Li, L Bao, C Gao |
Journal of Molecular Neuroscience | 2021 |
Mechanistic basis for receptor-mediated pathological α-synuclein fibril cell-to-cell transmission in Parkinson's disease
S Zhang, YQ Liu, C Jia, YJ Lim, G Feng, E Xu, H Long, Y Kimura, Y Tao, C Zhao, C Wang, Z Liu, JJ Hu, MR Ma, Z Liu, L Jiang, D Li, R Wang, VL Dawson, TM Dawson, YM Li, X Mao, C Liu |
Proceedings of the National Academy of Sciences | 2021 |
Chemoenzymatic Semi‐synthesis Enables Efficient Production of Isotopically Labeled α‐Synuclein with Site‐Specific Tyrosine Phosphorylation
B Pan, JH Park, T Ramlall, D Eliezer, E Rhoades, EJ Petersson |
Chembiochem : a European journal of chemical biology | 2021 |
Parkin interacting substrate phosphorylation by c-Abl drives dopaminergic neurodegeneration
H Kim, J Shin, A Jo, J Kim, S Park, J Choi, H Kang, V Dawson, T Dawson, J Shin, Y Lee |
Brain | 2021 |
Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity
M Werner, C Olanow |
Movement disorders : official journal of the Movement Disorder Society | 2021 |
The dual role of c‐src in cell‐to‐cell transmission of α‐synuclein
YR Choi, JB Kim, SJ Kang, HR Noh, I Jou, EH Joe, SM Park |
EMBO reports | 2020 |
Clinically Precedented Protein Kinases: Rationale for Their Use in Neurodegenerative Disease
CL Benn, LA Dawson |
Frontiers in aging neuroscience | 2020 |
In Search of Effective Treatments Targeting α-Synuclein Toxicity in Synucleinopathies: Pros and Cons
M Fouka, P Mavroeidi, G Tsaka, M Xilouri |
Frontiers in Cell and Developmental Biology | 2020 |
SUMOylation in α-Synuclein Homeostasis and Pathology
M Savyon, S Engelender |
Frontiers in aging neuroscience | 2020 |
Approaches to Disease Modification for Parkinson’s Disease: Clinical Trials and Lessons Learned
AY Hung, MA Schwarzschild |
Neurotherapeutics | 2020 |
PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson’s disease
P Ge, VL Dawson, TM Dawson |
Molecular Neurodegeneration | 2020 |
Chemoenzymatic Semisynthesis of Phosphorylated α-Synuclein Enables Identification of a Bidirectional Effect on Fibril Formation
B Pan, E Rhoades, EJ Petersson |
ACS chemical biology | 2020 |
α-Synucleinopathy associated c-Abl activation causes p53-dependent autophagy impairment
R Karim, EE Liao, J Kim, J Meints, HM Martinez, O Pletnikova, JC Troncoso, MK Lee |
Molecular Neurodegeneration | 2020 |
Development of a novel method for the quantification of tyrosine 39 phosphorylated α- and β-synuclein in human cerebrospinal fluid
CH Na, G Sathe, LS Rosenthal, AR Moghekar, VL Dawson, TM Dawson, A Pandey |
Clinical Proteomics | 2020 |
Parkinson’s disease-related phosphorylation at Tyr39 rearranges α-synuclein amyloid fibril structure revealed by cryo-EM
K Zhao, YJ Lim, Z Liu, H Long, Y Sun, JJ Hu, C Zhao, Y Tao, X Zhang, D Li, YM Li, C Liu |
Proceedings of the National Academy of Sciences | 2020 |
Current and emerging therapeutic targets for Parkinson’s disease
T Pingale, GL Gupta |
Metabolic Brain Disease | 2020 |
Keeping α-Synuclein at Bay: A More Active Role of Molecular Chaperones in Preventing Mitochondrial Interactions and Transition to Pathological States?
EE Aspholm, I Matečko-Burmann, BM Burmann |
Life Sciences | 2020 |
Looking Beyond the Core: The Role of Flanking Regions in the Aggregation of Amyloidogenic Peptides and Proteins
SM Ulamec, DJ Brockwell, SE Radford |
Frontiers in neuroscience | 2020 |
Amyloid-like oligomerization of AIMP2 contributes to α-synuclein interaction and Lewy-like inclusion
S Ham, SP Yun, H Kim, D Kim, BA Seo, H Kim, JY Shin, MA Dar, GH Lee, YI Lee, D Kim, S Kim, HS Kweon, JH Shin, HS Ko, Y Lee |
Science Translational Medicine | 2020 |
Oxidative stress in vagal neurons promotes Parkinsonian pathology and intercellular α-synuclein transfer
Ruth E Musgrove, Michael Helwig, Eun-Jin Bae, Helia Aboutalebi, Seung-Jae Lee, Ayse Ulusoy, Donato A. Di Monte |
Journal of Clinical Investigation | 2019 |
Multikinase Abl/DDR/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration
AJ Fowler, M Hebron, AA Missner, R Wang, X Gao, BT Kurd-Misto, X Liu, CE Moussa |
Drugs in R & D | 2019 |
Targeting α-Synuclein in Parkinson’s Disease: Progress Towards the Development of Disease-Modifying Therapeutics
D Savitt, J Jankovic |
Drugs | 2019 |
Alpha-synuclein suppresses mitochondrial protease ClpP to trigger mitochondrial oxidative damage and neurotoxicity
D Hu, X Sun, X Liao, X Zhang, S Zarabi, A Schimmer, Y Hong, C Ford, Y Luo, X Qi |
Acta Neuropathologica | 2019 |
Felodipine induces autophagy in mouse brains with pharmacokinetics amenable to repurposing
FH Siddiqi, FM Menzies, A Lopez, E Stamatakou, C Karabiyik, R Ureshino, T Ricketts, M Jimenez-Sanchez, MA Esteban, L Lai, MD Tortorella, Z Luo, H Liu, E Metzakopian, HJ Fernandes, A Bassett, E Karran, BL Miller, A Fleming, DC Rubinsztein |
Nature Communications | 2019 |
A Bcr-Abl Inhibitor GNF-2 Attenuates Inflammatory Activation of Glia and Chronic Pain
GJ Song, H Rahman, MK Jha, DP Gupta, SH Park, JH Kim, SH Lee, IK Lee, T Sim, YC Bae, WH Lee, K Suk |
Frontiers in pharmacology | 2019 |
Parkin interacting substrate zinc finger protein 746 is a pathological mediator in Parkinson’s disease
S Brahmachari, S Lee, S Kim, C Yuan, SS Karuppagounder, P Ge, R Shi, EJ Kim, A Liu, D Kim, S Quintin, H Jiang, M Kumar, SP Yun, TI Kam, X Mao, Y Lee, DA Swing, L Tessarollo, HS Ko, VL Dawson, TM Dawson |
Brain | 2019 |
Cell-Based Screen Using Amyloid Mimic β23 Expression Identifies Peucedanocoumarin III as a Novel Inhibitor of α-Synuclein and Huntingtin Aggregates
Sangwoo Ham, Hyojung Kim, Seojin Hwang, Hyunook Kang, Seung Pil Yun, Sangjune Kim, Donghoon Kim, Hyun Sook Kwon, Yun-Song Lee, MyoungLae Cho, Heung-Mook Shin, Heejung Choi, Ka Young Chung, Han Seok Ko, Gum Hwa Lee, Yunjong Lee |
Molecules and Cells | 2019 |
Regulation of α-synuclein by chaperones in mammalian cells
BM Burmann, JA Gerez, I Matečko-Burmann, S Campioni, P Kumari, D Ghosh, A Mazur, EE Aspholm, D Šulskis, M Wawrzyniuk, T Bock, A Schmidt, SG Rüdiger, R Riek, S Hiller |
Nature | 2019 |
Doublecortin-like Kinase 1 Regulates α-Synuclein Levels and Toxicity
GE Vázquez-Vélez, KA Gonzales, JP Revelli, CJ Adamski, FA Naini, A Bajić, E Craigen, R Richman, SM Heman-Ackah, MJ Wood, MW Rousseaux, HY Zoghbi |
The Journal of neuroscience : the official journal of the Society for Neuroscience | 2019 |
Kinase-Based Taming of Brain Microglia Toward Disease-Modifying Therapy
SH Lee, K Suk |
Frontiers in cellular neuroscience | 2018 |
Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease
SP Yun, TI Kam, N Panicker, SM Kim, Y Oh, JS Park, SH Kwon, YJ Park, SS Karuppagounder, H Park, S Kim, N Oh, NA Kim, S Lee, S Brahmachari, X Mao, JH Lee, M Kumar, D An, SU Kang, Y Lee, KC Lee, DH Na, D Kim, SH Lee, VV Roschke, SA Liddelow, Z Mari, BA Barres, VL Dawson, S Lee, TM Dawson, HS Ko |
Nature Medicine | 2018 |
The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson’s disease mouse model
S Lee, S Kim, YJ Park, SP Yun, SH Kwon, D Kim, DY Kim, JS Shin, DJ Cho, GY Lee, HS Ju, HJ Yun, JH Park, WR Kim, EA Jung, S Lee, HS Ko |
Human Molecular Genetics | 2018 |
Graphene quantum dots prevent α-synucleinopathy in Parkinson’s disease
D Kim, JM Yoo, H Hwang, J Lee, SH Lee, SP Yun, MJ Park, MJ Lee, S Choi, SH Kwon, S Lee, SH Kwon, S Kim, YJ Park, M Kinoshita, YH Lee, S Shin, SR Paik, SJ Lee, S Lee, BH Hong, HS Ko |
Nature Nanotechnology | 2018 |
Tetracycline repurposing in neurodegeneration: focus on Parkinson’s disease
M Bortolanza, GC Nascimento, SB Socias, D Ploper, RN Chehín, R Raisman-Vozari, E Del-Bel |
Journal of Neural Transmission | 2018 |
Phosphotyrosine profiling of human cerebrospinal fluid
G Sathe, CH Na, S Renuse, A Madugundu, M Albert, A Moghekar, A Pandey |
Clinical Proteomics | 2018 |
Levo-tetrahydropalmatine Attenuates Neuron Apoptosis Induced by Cerebral Ischemia–Reperfusion Injury: Involvement of c-Abl Activation
R Sun, Y Song, S Li, Z Ma, X Deng, Q Fu, R Qu, S Ma |
Journal of Molecular Neuroscience | 2018 |
Sensitivity and specificity of phospho-Ser129 α-synuclein monoclonal antibodies
V Delic, S Chandra, H Abdelmotilib, T Maltbie, S Wang, D Kem, HJ Scott, RN Underwood, Z Liu, LA Volpicelli-Daley, AB West |
The Journal of Comparative Neurology | 2018 |
Emerging Treatment Approaches for Parkinson’s Disease
TB Stoker, KM Torsney, RA Barker |
Frontiers in neuroscience | 2018 |
c-Abl Inhibition Exerts Symptomatic Antiparkinsonian Effects Through a Striatal Postsynaptic Mechanism
Y Zhou, Y Yamamura, M Ogawa, R Tsuji, K Tsuchiya, J Kasahara, S Goto |
Frontiers in pharmacology | 2018 |
The emerging link between O-GlcNAcylation and neurological disorders
X Ma, H Li, Y He, J Hao |
Cellular and Molecular Life Sciences | 2017 |
Involvement of c-Abl Kinase in Microglial Activation of NLRP3 Inflammasome and Impairment in Autolysosomal System
V Lawana, N Singh, S Sarkar, A Charli, H Jin, V Anantharam, AG Kanthasamy, A Kanthasamy |
Journal of Neuroimmune Pharmacology | 2017 |
T cells from patients with Parkinson’s disease recognize α-synuclein peptides
D Sulzer, RN Alcalay, F Garretti, L Cote, E Kanter, J Agin-Liebes, C Liong, C McMurtrey, WH Hildebrand, X Mao, VL Dawson, TM Dawson, C Oseroff, J Pham, J Sidney, MB Dillon, C Carpenter, D Weiskopf, E Phillips, S Mallal, B Peters, A Frazier, CS Arlehamn, A Sette |
Nature | 2017 |
The c-Abl inhibitor in Parkinson disease
ZH Zhou, YF Wu, X Wang, YZ Han |
Neurological Sciences | 2017 |
Mechanisms of Parkinson’s disease-related proteins in mediating secondary brain damage after cerebral ischemia
TH Kim, R Vemuganti |
Journal of Cerebral Blood Flow & Metabolism | 2017 |
Progress toward an integrated understanding of Parkinson’s disease
MW Rousseaux, JM Shulman, J Jankovic |
F1000Research | 2017 |
CRISPR-Cas9 Mediated Telomere Removal Leads to Mitochondrial Stress and Protein Aggregation
H Kim, S Ham, M Jo, G Lee, YS Lee, JH Shin, Y Lee |
International journal of molecular sciences | 2017 |
Ubiquitin and Parkinson's disease through the looking glass of genetics
H Walden, MM Muqit |
Biochemical Journal | 2017 |
c-Abl and Parkinson’s Disease: Mechanisms and Therapeutic Potential
S Brahmachari, SS Karuppagounder, P Ge, S Lee, VL Dawson, TM Dawson, HS Ko |
Journal of Parkinson's disease | 2017 |
Nilotinib – Differentiating the Hope from the Hype
RK Wyse, P Brundin, TB Sherer |
Journal of Parkinson's disease | 2016 |
c-Abl Inhibitors Enable Insights into the Pathophysiology and Neuroprotection in Parkinson’s Disease
D Lindholm, DD Pham, A Cascone, O Eriksson, K Wennerberg, M Saarma |
Frontiers in aging neuroscience | 2016 |
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd |
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology | 2009 |